<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270060" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39822950</article-id><article-id pub-id-type="pmc">PMC11736286</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70060</article-id><article-id pub-id-type="publisher-id">DEO270060</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Post&#x02010;endoscopic sphincterotomy delayed bleeding occurs in patients with just 1&#x02010;day interruption of direct oral anticoagulants or hemodialysis</article-title><alt-title alt-title-type="left-running-head">HASEGAWA <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270060-cr-0001" contrib-type="author" corresp="yes"><name><surname>Hasegawa</surname><given-names>Sho</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1671-0643</contrib-id><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>t166064d@yokohama-cu.ac.jp</email></address></contrib><contrib id="deo270060-cr-0002" contrib-type="author"><name><surname>Kurita</surname><given-names>Yusuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2482-6707</contrib-id><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0003" contrib-type="author"><name><surname>Yamazaki</surname><given-names>Yuma</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0004" contrib-type="author"><name><surname>Nihei</surname><given-names>Shinichi</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0005" contrib-type="author"><name><surname>Iizuka</surname><given-names>Takeshi</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0006" contrib-type="author"><name><surname>Misawa</surname><given-names>Noboru</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0007" contrib-type="author"><name><surname>Hosono</surname><given-names>Kunihiro</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0008" contrib-type="author"><name><surname>Endo</surname><given-names>Itaru</given-names></name><xref rid="deo270060-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270060-cr-0009" contrib-type="author"><name><surname>Kobayashi</surname><given-names>Noritoshi</given-names></name><xref rid="deo270060-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270060-cr-0010" contrib-type="author"><name><surname>Kubota</surname><given-names>Kensuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6767-0410</contrib-id><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270060-cr-0011" contrib-type="author"><name><surname>Nakajima</surname><given-names>Atsushi</given-names></name><xref rid="deo270060-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270060-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Yokohama City University Graduate School of Medicine</institution>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270060-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterological Surgery</named-content>
<institution>Yokohama City University Graduate School of Medicine</institution>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270060-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Oncology</named-content>
<institution>Yokohama City University Graduate School of Medicine</institution>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Sho Hasegawa, Department of Gastroenterology and Hepatology Yokohama City University Graduate School of Medicine 3&#x02010;9, Fuku&#x02010;ura, Kanazawa&#x02010;ku, Yokohama 236&#x02010;0004, Japan.<break/> Email: <email>t166064d@yokohama-cu.ac.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="35">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70060</elocation-id><history>
<date date-type="rev-recd"><day>10</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>12</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>31</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70060.pdf"/><abstract><title>Abstract</title><sec id="deo270060-sec-0010"><title>Objective</title><p>Endoscopic sphincterotomy (EST), especially when anticoagulants are used, carries a significant risk of delayed bleeding. However, the relationship between the use of antithrombotic agents, including direct oral anticoagulants, and post&#x02010;EST bleeding remains unclear. This study aimed to identify the risk factors for post&#x02010;EST delayed bleeding when antithrombotic agents were administered according to the guidelines.</p></sec><sec id="deo270060-sec-0020"><title>Methods</title><p>We analyzed cases of patients who underwent endoscopic retrograde cholangiopancreatography and EST between January 2018 and August 2022, focusing on those with normal anatomy and na&#x000ef;ve papillae. We examined the incidence of post&#x02010;EST bleeding, endoscopic retrograde cholangiopancreatography procedure details, severity and timing of post&#x02010;EST delayed bleeding, hemostatic interventions, and factors related to post&#x02010;EST delayed bleeding.</p></sec><sec id="deo270060-sec-0030"><title>Results</title><p>Among the 502 patients included, 76 (15%) were taking antithrombotic agents. Post&#x02010;endoscopic retrograde cholangiopancreatography&#x000a0;delayed bleeding was noted in seven patients (1.4%). Mild, moderate, and severe delayed bleeding occurred in four, one, and two cases, respectively. Hemostatic injection completely controlled cases of delayed bleeding. Multivariate analysis identified a 1&#x02010;day direct oral anticoagulants interruption (odds ratio: 20.5, 95% confidence interval: 3.33&#x02013;125, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.0011) and dialysis (odds ratio: 38.7, 95% confidence interval: 2.4&#x02013;624, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.0099) as significant risk factors for delayed bleeding. No thromboembolic events related to the discontinuation of antithrombotic drugs were observed.</p></sec><sec id="deo270060-sec-0040"><title>Conclusion</title><p>A 1&#x02010;day direct oral anticoagulants interruption and dialysis are independent risk factors for post&#x02010;EST delayed bleeding, necessitating careful consideration.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270060-kwd-0001">bleeding</kwd><kwd id="deo270060-kwd-0002">dialysis</kwd><kwd id="deo270060-kwd-0003">endoscopic sphincterotomy</kwd><kwd id="deo270060-kwd-0004">ERCP</kwd><kwd id="deo270060-kwd-0005">oral anticoagulant</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="7"/><word-count count="4055"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270060-sec-0050"><title>INTRODUCTION</title><p>Endoscopic sphincterotomy (EST) is a basic and established technique used in endoscopic retrograde cholangiopancreatography (ERCP), the utility of which is well established. However, it is associated with a high risk of bleeding, including intraoperative and delayed bleeding. Delayed bleeding can lead to major hemorrhage and often poses marked clinical challenges.<xref rid="deo270060-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> It is reported to occur at a frequency of 1&#x02013;2%,<xref rid="deo270060-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270060-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo270060-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> and risk factors include dialysis and heparin bridging for warfarin.<xref rid="deo270060-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270060-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> In recent years, management with antithrombotic agents, including direct oral anticoagulants (DOACs), has been established according to the Japan Gastroenterological Endoscopy Society (JGES).<xref rid="deo270060-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270060-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Since patients receiving antithrombotic therapy have a higher risk of bleeding, the guidelines of the European Society of Gastrointestinal Endoscopy, American Society for Gastrointestinal Endoscopy, and Asian Pacific Association of Gastroenterology recommend longer interruption periods for DOACs than that recommended by the JGES.<xref rid="deo270060-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo270060-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270060-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> However, evidence remains weak, and the fragile relationship between the interruption period and the risk of post&#x02010;EST bleeding remains a topic of debate. DOACs are promising in presenting a lower risk of gastrointestinal bleeding compared to warfarin<xref rid="deo270060-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>; however, there are few reports on post&#x02010;EST bleeding following guideline&#x02010;based management with DOACs.</p><p>Regarding the antiplatelet agents used during endoscopic treatment, continuation of aspirin monotherapy is recommended considering the embolism risk, because it does not exacerbate bleeding.<xref rid="deo270060-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270060-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo270060-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270060-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, reports suggesting that the continuation of antiplatelet monotherapy increases the risk of post&#x02010;EST bleeding have made this issue controversial.<xref rid="deo270060-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> At present, the relationship between antithrombotic management according to the JGES guidelines and post&#x02010;EST bleeding remains unclear. Hence, this study aimed to identify the risk factors for post&#x02010;EST bleeding when antithrombotic agents are used according to the JGES guidelines.</p></sec><sec id="deo270060-sec-0060"><title>METHODS</title><sec id="deo270060-sec-0070"><title>Patients</title><p>This study was approved by the Ethics Committee of Yokohama City University (F221100031). Data of patients who underwent ERCP at Yokohama City University Hospital between January 2018 and August 2022 were reviewed, and those of 502 patients with normal anatomy and untreated papillae who underwent EST were analyzed. The procedures described were performed in accordance with the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all participants by using an opt&#x02010;out approach.</p></sec><sec id="deo270060-sec-0080"><title>Endoscopic procedure</title><p>In all cases, ERCP was performed under fluoroscopic guidance. A JF&#x02010;260&#x000a0;V or TJF&#x02010;260&#x000a0;V scope was used, and sedation was achieved using pentazocine, midazolam, diazepam, or propofol when needed. EST was performed after bile duct cannulation and cholangiography using Clever Cut 3&#x000a0;V (Olympus Medical Systems). The electrosurgical unit used during EST was the ICC 200, which was set to 120&#x000a0;W in the Endocut mode. EST was performed in combination with endoscopic papillary large balloon dilatation (EPLBD) as needed. Bile duct stone extraction or biliary stent placement was performed depending on the case. Stone removal was performed using a mechanical lithotripter, basket, or balloon catheter. For the removal of large stones, electrohydraulic lithotripsy under cholangioscopy was used in combination with the aforementioned measure. For bile duct strictures, balloon dilation, plastic or metal stent placement, or endoscopic nasobiliary drainage (ENBD) was performed. Endoscopic hemostasis was achieved using local injection of hypertonic saline epinephrine (HSE), thrombin application, and clipping.</p></sec><sec id="deo270060-sec-0090"><title>Anticoagulant drug management</title><p>Based on the Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment,<xref rid="deo270060-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270060-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> instructions for medication were provided for EST because the procedure is associated with a high risk of bleeding. Regarding antiplatelet agent use, EST was performed without interruption if the patient was on only aspirin or cilostazol. If the patient was receiving clopidogrel, it was replaced with aspirin or cilostazol before the procedure. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban were discontinued on the morning of the ERCP, and EST was performed, with medication reinitiation on the following morning. The resumption of DOAC administration was postponed in cases where overt bleeding or worsening anemia, suggestive of post&#x02010;EST bleeding, was observed. If the patient was on warfarin, a temporary switch to DOACs was made if possible; if not, warfarin was discontinued and heparin replacement was used. Heparin was discontinued on the morning of the EST day and restarted 2&#x000a0;h after the procedure. EST was not performed in cases where the discontinuation of two or more antiplatelet agents or a combination of antiplatelet agents and DOACs was not feasible. In dialysis patients, nafamostat mesylate was used for hemodialysis during the hospitalization period for ERCP, while heparin was used after discharge.</p></sec><sec id="deo270060-sec-0100"><title>Definition of bleeding</title><p>ERCP&#x02010;related bleeding was classified as immediate or delayed. Immediate bleeding was defined as active bleeding requiring hemostatic treatment during ERCP or within 24&#x000a0;h after the procedure. Delayed bleeding was defined as a decrease of &#x02265;2&#x000a0;g/dL in the hemoglobin level occurring 24&#x000a0;h or later, accompanied by overt signs, such as hematemesis or melena, or symptoms of circulatory failure due to anemia, requiring second&#x02010;look endoscopy (Figure <xref rid="deo270060-fig-0001" ref-type="fig">1</xref>). Bleeding severity was classified into three grades using the Cotton classification: mild, moderate, and severe.<xref rid="deo270060-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p></sec><sec id="deo270060-sec-0110"><title>Outcomes</title><p>The primary outcome was the incidence of post&#x02010;EST bleeding. The incidence of intraoperative bleeding during EST, the details of the ERCP procedure, severity and timing of post&#x02010;EST delayed bleeding, hemostatic methods, and factors associated with post&#x02010;EST delayed bleeding were also analyzed.</p></sec><sec id="deo270060-sec-0120"><title>Statistical analysis</title><p>Categorical variables were compared using the chi&#x02010;squared test or Fisher's exact test. For continuous data, the Student's <italic toggle="yes">t</italic>&#x02010;test or Mann&#x02010;Whitney <italic toggle="yes">U</italic> test was used. Multivariate logistic regression analysis was performed. Statistical significance was set at <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05. Statistical analyses were performed using JMP Pro (version 16.0; SAS Institute, Inc.).</p></sec></sec><sec id="deo270060-sec-0130"><title>RESULTS</title><sec id="deo270060-sec-0140"><title>Patient characteristics</title><p>Among the 502 patients, 299 were male (59%) and the median patient age was 72 years. The primary conditions were bile duct stones, pancreatic cancer, bile duct cancer, benign bile duct strictures, and acute cholecystitis in 209 (42%), 121 (24%), 106 (21%), 34 (6.7%), and 10 (2.4%) patients, respectively. Comorbidities included cardiovascular disease, intracerebral hemorrhage, cerebral infarction, Child&#x02010;Pugh C liver cirrhosis, chronic kidney failure on maintenance dialysis, and cholangitis in 81 (16%), 22 (4.3%), eight (1.6%), seven (1.3%), five (1%), and 139 (27%) patients, respectively. Antithrombotic drug use was observed in 76 patients (15%): 45 (8.9%), 26 (5.1%), and nine (1.7%) patients were on single antiplatelet therapy, DOACs, and warfarin with heparin bridging, respectively. No cases of coagulation abnormalities that would preclude EST were identified before ERCP (Table&#x000a0;<xref rid="deo270060-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="deo270060-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" rowspan="1" colspan="1">502</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, male, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">299 (59)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, median (range)</td><td align="left" rowspan="1" colspan="1">72 (20&#x02013;93)</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary disease, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bile duct stone</td><td align="left" rowspan="1" colspan="1">209 (42)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatic cancer</td><td align="left" rowspan="1" colspan="1">121 (24)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bile duct cancer</td><td align="left" rowspan="1" colspan="1">106 (21)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Benign biliary structure</td><td align="left" rowspan="1" colspan="1">34 (6.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymph node metastasis of other cancers</td><td align="left" rowspan="1" colspan="1">22 (4.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cholecystitis</td><td align="left" rowspan="1" colspan="1">10 (2.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Underlying disease</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardiovascular disease</td><td align="left" rowspan="1" colspan="1">81 (16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cerebral hemorrhage</td><td align="left" rowspan="1" colspan="1">22 (4.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">8 (1.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Liver cirrhosis</td><td align="left" rowspan="1" colspan="1">7 (1.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemodialysis</td><td align="left" rowspan="1" colspan="1">5 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholangitis</td><td align="left" rowspan="1" colspan="1">139 (27)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antithrombotic medications</td><td align="left" rowspan="1" colspan="1">76 (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiplatelet agents</td><td align="left" rowspan="1" colspan="1">45 (8.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">DOACs</td><td align="left" rowspan="1" colspan="1">26 (5.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heparin bridging of warfarin</td><td align="left" rowspan="1" colspan="1">9 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">PT&#x02010;INR (IQR)</td><td align="left" rowspan="1" colspan="1">1.07 (1.02&#x02013;1.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">APTT, second (IQR)</td><td align="left" rowspan="1" colspan="1">32.1 (29.8&#x02013;34.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count, /&#x000b5;L (IQR)</td><td align="left" rowspan="1" colspan="1">21.2 (16.6&#x02013;26.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR</td><td align="left" rowspan="1" colspan="1">73.3 (59.7&#x02013;88.3)</td></tr></tbody></table><table-wrap-foot><fn id="deo270060-tbl1-note-0001"><p>Abbreviations: APTT, activated partial thromboplastin time; DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; PT&#x02010;INR, prothrombin time&#x02010;international normalized ratio.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270060-sec-0150"><title>ERCP procedure and complications</title><p>ERCP procedures included biliary drainage, stone removal, and diagnosis only in 311 (62%), 175 (34%), and 22 (4%) cases, respectively. The biliary drainage involved the use of plastic stents, self&#x02010;expandable metal stents (SEMS), and ENBD in 172 (34%), 113 (20%), and 26 (5%) cases, respectively. The periampullary diverticulum was observed in 92 cases (18%). The incision size for EST was small in 435 cases (87%) and medium in 76 cases (13%), with no cases requiring a large incision. EST was performed in combination with EPLBD in 31 cases (6.1%). The average procedure time for ERCP (range) was 30&#x000a0;min (range; 7&#x02013;120&#x000a0;min). Intraoperative bleeding occurred in 44 patients (8.7%). Other complications included post&#x02010;ERCP pancreatitis, cholecystitis, and cholangitis in 70 (14%), nine (1.7%), and seven (1.4%) cases, respectively. Of the post&#x02010;ERCP pancreatitis cases, 51 (10%), 11 (2%), and 8 (1.5%) were mild, moderate, and severe, respectively (Table&#x000a0;<xref rid="deo270060-tbl-0002" ref-type="table">2</xref>). No thromboembolic events related to the discontinuation of antithrombotic drugs were observed.</p><table-wrap position="float" id="deo270060-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Endoscopic retrograde cholangiopancreatographyprocedure and complications.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Purpose</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stone removal</td><td align="left" rowspan="1" colspan="1">175 (34)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Biliary drainage</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Plastic stent</td><td align="left" rowspan="1" colspan="1">172 (34)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SEMS</td><td align="left" rowspan="1" colspan="1">107 (21)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ENBD</td><td align="left" rowspan="1" colspan="1">26 (5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diagnosis, biopsy</td><td align="left" rowspan="1" colspan="1">22 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedure time, min (range)</td><td align="left" rowspan="1" colspan="1">30 (7&#x02013;120)</td></tr><tr><td align="left" rowspan="1" colspan="1">Periampullary diverticulum, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">92 (18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of the EST incision, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">435 (87)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Medium</td><td align="left" rowspan="1" colspan="1">67 (13)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Full</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination with EPLBD, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">31 (6.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse event without post&#x02010;EST delayed bleeding, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intraoperative bleeding</td><td align="left" rowspan="1" colspan="1">44 (8.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreatitis</td><td align="left" rowspan="1" colspan="1">70 (14)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">51 (10)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">11 (2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">8 (1.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cholecystitis</td><td align="left" rowspan="1" colspan="1">9 (1.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cholangitis</td><td align="left" rowspan="1" colspan="1">7 (1.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Perforation</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn id="deo270060-tbl2-note-0001"><p>Abbreviations: ENBD, endoscopic nasobiliary drainage; EPLBD, endoscopic papillary large balloon dilatation.; ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; SEMS, self&#x02010;expandable metallic stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270060-sec-0160"><title>Incidence, timing, and management of post&#x02010;EST delayed bleeding</title><p>Delayed bleeding after ERCP occurred in seven patients (1.4%). Delayed bleeding occurred at the following time points: between 24 and 48&#x000a0;h, two cases; between 48 and 72&#x000a0;h, two cases; and after 72&#x000a0;h, three cases. The severity of bleeding was mild, moderate, and severe in four, one, and two cases, respectively. All cases of delayed bleeding were managed using HSE injections for primary hemostasis, and clipping was performed in only one case (Table&#x000a0;<xref rid="deo270060-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="deo270060-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Details of post&#x02010;endoscopic sphincterotomy delayed bleeding.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Post&#x02010;EST delayed bleeding</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Incidence, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">7 (1.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Time to diagnose, median (range)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02013;48 h</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">48&#x02013;72 h</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x000a0;&#x0003e;72 h</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severity grading</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Method of hemostasis</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HSE injection</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clipping</td><td align="left" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="deo270060-tbl3-note-0001"><p>Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; HSE, hypertonic saline epinephrine solution.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270060-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Multivariate analysis of factors associated with post&#x02010;endoscopic sphincterotomy delayed bleeding.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Bleeding (<italic toggle="yes">n</italic>&#x000a0;= 7)</th><th align="left" rowspan="1" colspan="1">No bleeding (<italic toggle="yes">n</italic>&#x000a0;= 495)</th><th align="left" rowspan="1" colspan="1">Univariate analysis, <italic toggle="yes">p</italic>&#x02010;value</th><th align="left" rowspan="1" colspan="1">Multivariate analysis, <italic toggle="yes">p</italic>&#x02010;value</th><th align="left" rowspan="1" colspan="1">Odds ratio</th><th align="left" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age,&#x000a0;&#x0003e;75 years</td><td align="left" rowspan="1" colspan="1">4 (57%)</td><td align="left" rowspan="1" colspan="1">207 (41%)</td><td align="left" rowspan="1" colspan="1">0.4610</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Malignant disease</td><td align="left" rowspan="1" colspan="1">2 (29%)</td><td align="left" rowspan="1" colspan="1">247 (50%)</td><td align="left" rowspan="1" colspan="1">0.4499</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cholangitis</td><td align="left" rowspan="1" colspan="1">1 (14%)</td><td align="left" rowspan="1" colspan="1">138 (28%)</td><td align="left" rowspan="1" colspan="1">0.6794</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Periampullary diverticulum</td><td align="left" rowspan="1" colspan="1">3 (43%)</td><td align="left" rowspan="1" colspan="1">89 (18%)</td><td align="left" rowspan="1" colspan="1">0.1191</td><td align="left" rowspan="1" colspan="1">0.5401</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.29&#x02013;10.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Median incision range for EST</td><td align="left" rowspan="1" colspan="1">2(28%)</td><td align="left" rowspan="1" colspan="1">65 (13%)</td><td align="left" rowspan="1" colspan="1">0.2371</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Combination with EPLBD</td><td align="left" rowspan="1" colspan="1">2 (28%)</td><td align="left" rowspan="1" colspan="1">29 (5.8%)</td><td align="left" rowspan="1" colspan="1">0.0639</td><td align="left" rowspan="1" colspan="1">0.0662</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">0.88&#x02013;37.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Biliary stenting</td><td align="left" rowspan="1" colspan="1">5 (71%)</td><td align="left" rowspan="1" colspan="1">300 (61%)</td><td align="left" rowspan="1" colspan="1">0.7098</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SEMS replacement</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">107 (21%)</td><td align="left" rowspan="1" colspan="1">0.3547</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">During bleeding</td><td align="left" rowspan="1" colspan="1">2 (29%)</td><td align="left" rowspan="1" colspan="1">42 (8.4%)</td><td align="left" rowspan="1" colspan="1">0.1189</td><td align="left" rowspan="1" colspan="1">0.0559</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">0.92&#x02013;45.2</td></tr><tr><td align="left" rowspan="1" colspan="1">PT&#x02010;INR&#x000a0;&#x0003e;1.5</td><td align="left" rowspan="1" colspan="1">1 (14%)</td><td align="left" rowspan="1" colspan="1">17 (3.4%)</td><td align="left" rowspan="1" colspan="1">0.2268</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Antiplatelet agent</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">45 (9%)</td><td align="left" rowspan="1" colspan="1">1.0000</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DOACs</td><td align="left" rowspan="1" colspan="1">3 (43%)</td><td align="left" rowspan="1" colspan="1">23 (4.6%)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0038</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0011</bold>
</td><td align="left" rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">3.33&#x02013;125</td></tr><tr><td align="left" rowspan="1" colspan="1">Heparin bridging of warfarin</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">9 (1.8%)</td><td align="left" rowspan="1" colspan="1">1.0000</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Liver cirrhosis</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">1 (0.2%)</td><td align="left" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hemodialysis</td><td align="left" rowspan="1" colspan="1">1 (14%)</td><td align="left" rowspan="1" colspan="1">4 (0.8%)</td><td align="left" rowspan="1" colspan="1">0.0681</td><td align="left" rowspan="1" colspan="1">
<bold>0.0099</bold>
</td><td align="left" rowspan="1" colspan="1">38.7</td><td align="left" rowspan="1" colspan="1">2.4&#x02013;624</td></tr></tbody></table><table-wrap-foot><fn id="deo270060-tbl4-note-0001"><p>Abbreviations: DOAC, direct oral anticoagulant.; EPLBD, endoscopic papillary large balloon dilatation; ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; PT&#x02010;INR, prothrombin time&#x02010;international normalized ratio; SEMS, self&#x02010;expandable metallic stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270060-sec-0170"><title>Factors related to delayed bleeding</title><p>Univariate analysis identified DOAC use as a significant risk factor for delayed bleeding among factors such as age (75 years or older), malignant disease, presence of cholangitis or periampullary diverticulum, medium&#x02010;sized incision EST, EST performed in combination with EPLBD, bile duct stent placement, intraoperative bleeding, continuation of antiplatelet therapy, 1&#x02010;day DOAC interruption, heparin bridging, liver cirrhosis (Child&#x02010;Pugh C), and dialysis (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.0038). Multivariate analysis using ERCP&#x02010;related bleeding, 1&#x02010;day DOAC interruption, and dialysis as variables identified 1&#x02010;day DOAC interruption (odds ratio [OR]: 20.5, 95% confidence interval [CI]: 3.33&#x02013;125, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.0011) and dialysis (OR: 38.7, 95% CI: 2.4&#x02013;624, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.009) as significant risk factors for delayed bleeding (Table <xref rid="deo270060-tbl-0004" ref-type="table">4</xref>).</p></sec></sec><sec id="deo270060-sec-0180"><title>DISCUSSION</title><p>In this study, we evaluated the data of patients who underwent ERCP according to the JGES guidelines for management with antithrombotic drugs and examined the results related to post&#x02010;EST delayed bleeding. We found that a 1&#x02010;day interruption of DOACs was a significant risk factor for post&#x02010;EST delayed bleeding. Receipt of maintenance dialysis was also identified as a significant risk factor. In contrast, the continuation of single antiplatelet therapy was not a risk factor for delayed bleeding. Thromboembolic events were not observed in the patients studied.</p><p>EST is a high&#x02010;risk procedure, and post&#x02010;EST bleeding presents clinical challenges. In this study, the frequency of post&#x02010;EST bleeding was 1.4%, which is consistent with previously reported rates of 1%&#x02013;4%,<xref rid="deo270060-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270060-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="deo270060-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270060-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> indicating that the post&#x02010;EST bleeding rate in this study is reasonable. The responses to post&#x02010;EST bleeding included clipping, HSE injection, balloon tamponade, and argon plasma coagulation. In all cases, primary hemostasis was achieved using HSE injections, with clipping performed in one case involving a dialysis patient. None of the patients required arterial embolization or surgery. Since post&#x02010;EST bleeding can sometimes be significant and present clinical issues, it is essential to remain vigilant.</p><p>A 1&#x02010;day interruption of DOACs was identified as a significant risk factor for post&#x02010;EST bleeding. Given that DOACs have a short half&#x02010;life of approximately 12&#x000a0;h, a 1&#x02010;day interruption before EST, as per the JGES guidelines, is considered reasonable. However, because peak plasma concentrations of DOACs are reached within 1&#x02013;3&#x000a0;h after administration<xref rid="deo270060-bib-0020" ref-type="bibr">,<sup>20</sup>
</xref> resuming medication could lead to a sudden increase in bleeding tendency and potentially trigger delayed bleeding. In our study, the resumption of DOACs on the day after EST was associated with subsequent bleeding. Guidelines on DOAC management during EST vary among countries. The American Society for Gastrointestinal Endoscopy and the European Society of Gastrointestinal Endoscopy recommends resuming medication 1&#x02013;3 and 2&#x02013;3 days after the procedure, respectively, while the JGES recommends resumption on the day after the procedure. Japanese reports suggest that an interruption of more than 1&#x02010;day results in fewer post&#x02010;EST bleeding events than an interruption of 1 day.<xref rid="deo270060-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Furthermore, meta&#x02010;analyses of antithrombotic drug use showed that a 1&#x02010;day interruption did not significantly reduce the bleeding risk.<xref rid="deo270060-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Although Western guidelines consider bleeding risks when setting interruption periods, there is also the risk of thromboembolic events during the interruption period. In this study, because all cases involved a 1&#x02010;day interruption, the absence of thromboembolic events suggests that the JGES guidelines are acceptable. However, because this study found that a 1&#x02010;day interruption of DOACs was a significant risk factor for delayed bleeding, further investigation into the optimal timing for resuming DOACs is needed. For patients with a low risk of embolism, delaying the resumption of DOACs after EST might be considered.</p><p>In recent years, the utility of combining small EST with EPBD (ESBD) or with EPLBD (ESLBD) has been reported.<xref rid="deo270060-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> ESBD for small stones is associated with a significantly lower incidence of bleeding compared with EST<xref rid="deo270060-bib-0023" ref-type="bibr">,<sup>23</sup>
</xref> suggesting it may be a safer option for patients with a bleeding tendency. On the other hand, for large stones, ESLBD has been reported to be associated with a similar incidence of bleeding as EST.<xref rid="deo270060-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>In this study, only 6.1% of cases underwent ESLBD, and it was not identified as a risk factor for either intraoperative or post&#x02010;EST delayed bleeding. For patients with a tendency to bleed, ESBD or ESLBD should be considered as potential options in future clinical practice.</p><p>Reports have indicated that hemodialysis in patients with chronic renal failure is a risk factor for post&#x02010;EST bleeding.<xref rid="deo270060-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270060-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270060-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="deo270060-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Multivariate analysis in this study also identified hemodialysis as a significant risk factor for post&#x02010;EST bleeding, consistent with previous reports. Patients undergoing hemodialysis for chronic renal failure are believed to have higher bleeding tendencies owing to impaired platelet function and intermittent anticoagulant use. Although only five patients on hemodialysis were included in this study, it is essential to consider the increased risk of post&#x02010;EST bleeding when performing EST in such patients.</p><p>However, continued use of aspirin monotherapy was not identified as a risk factor for post&#x02010;EST delayed bleeding. Although some meta&#x02010;analyses have shown that aspirin increases the risk of post&#x02010;EST bleeding,<xref rid="deo270060-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> there are also reports indicating that aspirin monotherapy does not significantly increase bleeding risk.<xref rid="deo270060-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270060-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo270060-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Various guidelines indicate that aspirin therapy can be continued during EST.<xref rid="deo270060-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270060-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo270060-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The results of this study support the safety of continued aspirin therapy during EST according to the guidelines.</p><p>Intraoperative bleeding during EST was not a significant risk factor for post&#x02010;EST delayed bleeding in this study. However, intraoperative bleeding has been reported as a risk factor for post&#x02010;EST bleeding in a large retrospective study.<xref rid="deo270060-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> In the present study, too, multivariate analysis revealed that intraoperative bleeding tended to be a risk factor for post&#x02010;EST bleeding (OR&#x000a0;=&#x000a0;6.4; 95% CI: 0.92&#x02013;45.2; <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.0559). If more cases are identified, it may be extracted as a significant risk factor, and patients with intraoperative bleeding during EST should be cautioned against post&#x02010;EST bleeding as well. We also analyzed risk factors associated with intraoperative bleeding during EST (Table <xref rid="deo270060-supitem-0001" ref-type="supplementary-material">S1</xref>) and found that 1&#x02010;day withdrawal of DOACs and maintenance dialysis, which were identified as risk factors for post&#x02010;EST bleeding, were not risk factors for intraoperative bleeding. They were also not associated with the use of antiplatelet agents. Therefore, we believe that intraoperative bleeding can be safely treated with antithrombotic agents according to the guidelines.</p><p>This study has several limitations. One limitation is that it is a single&#x02010;center, retrospective analysis, which introduces the possibility of selection bias. Therefore, large&#x02010;scale validation across multiple centers is required. Additionally, post&#x02010;EST bleeding is a relatively rare complication compared with ERCP&#x02010;related pancreatitis, resulting in a low incidence rate.</p><p>In conclusion, 1&#x02010;day interruption of DOACs and hemodialysis are independent risk factors for post&#x02010;EST bleeding. For patients with a low risk of embolism, delaying the resumption of DOACs after EST might be considered.</p></sec><sec sec-type="COI-statement" id="deo270060-sec-0200"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270060-sec-0210"><title>ETHICS STATEMENT</title><p>Approval of the research protocol by an Institutional Reviewer Board: The study was approved by the ethics committee of Yokohama City University (F221100031).</p></sec><sec id="deo270060-sec-0220"><title>PATIENT CONSENT STATEMENT</title><p>Informed consent was obtained from all participants by using an opt&#x02010;out approach.</p></sec><sec id="deo270060-sec-0230"><title>CLINICAL TRIAL REGISTRATION</title><p>N/A.</p></sec><sec id="deo270060-sec-0240"><fig position="float" fig-type="FIGURE" id="deo270060-fig-0001"><label>FIGURE 1</label><caption><p>Endoscopic images of post&#x02010;EST bleeding. (a) Papilla during EST. (b) Papilla 2 days after EST, showing evidence of bleeding. EST: endoscopic sphincterotomy.</p></caption><graphic xlink:href="DEO2-5-e70060-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270060-supitem-0001" position="float" content-type="local-data"><caption><p>Supplemental Table 1. Multivariate analysis of the factors associated with intraoperative bleeding during EST.</p></caption><media xlink:href="DEO2-5-e70060-s001.docx"/></supplementary-material></sec></body><back><ack id="deo270060-sec-0190"><title>ACKNOWLEDGMENTS</title><p>The authors are grateful to Naho Kobayashi, Ayako Ujiie, and Yoshiko&#x000a0;Yamazaki of Yokohama City University for their assistance with this study.</p></ack><ref-list id="deo270060-bibl-0001"><title>REFERENCES</title><ref id="deo270060-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270060-cit-0001">
<string-name>
<surname>Kahaleh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>M</given-names>
</string-name>. <article-title>Prevention and management of post&#x02010;endoscopic retrograde cholangiopancreatography complications</article-title>. <source>Clin Endosc</source>
<year>2012</year>; <volume>45</volume>: <fpage>305</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">22977824</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270060-cit-0002">
<string-name>
<surname>Ikarashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Katanuma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kin</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Factors associated with delayed hemorrhage after endoscopic sphincterotomy: Japanese large single&#x02010;center experience</article-title>. <source>J Gastroenterol</source>
<year>2017</year>; <volume>52</volume>: <fpage>1258</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">28478523</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270060-cit-0003">
<string-name>
<surname>Freeman</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Complications of endoscopic biliary sphincterotomy</article-title>. <source>N Engl J Med</source>
<year>1996</year>; <volume>335</volume>: <fpage>909</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">8782497</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270060-cit-0004">
<string-name>
<surname>Hamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yasunaga</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakai</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents</article-title>. <source>Endoscopy</source>
<year>2015</year>; <volume>47</volume>: <fpage>997</fpage>&#x02013;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">26126160</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270060-cit-0005">
<string-name>
<surname>Nakaji</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirata</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Matsui</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Hemodialysis is a strong risk factor for post&#x02010;endoscopic sphincterotomy bleeding in patients with choledocholithiasis</article-title>. <source>Endosc Int Open</source>
<year>2018</year>; <volume>6</volume>: <fpage>E568</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">29756014</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270060-cit-0006">
<string-name>
<surname>Fujimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fujishiro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment</article-title>. <source>Dig Endosc</source>
<year>2014</year>; <volume>26</volume>: <fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="deo270060-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270060-cit-0007">
<string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hokimoto</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 Appendix on anticoagulants including direct oral anticoagulants</article-title>. <source>Dig Endosc</source>
<year>2018</year>; <volume>30</volume>: <fpage>433</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29733468</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270060-cit-0008">
<string-name>
<surname>Chan</surname>
<given-names>FKL</given-names>
</string-name>, <string-name>
<surname>Goh</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines</article-title>. <source>Gut</source>
<year>2018</year>; <volume>67</volume>: <fpage>405</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">29331946</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270060-cit-0009">
<string-name>
<surname>Veitch</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Vanbiervliet</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gershlick</surname>
<given-names>AH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines</article-title>. <source>Gut</source>
<year>2016</year>; <volume>65</volume>: <fpage>374</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">26873868</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270060-cit-0010">
<string-name>
<surname>Acosta</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Abraham</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Chandrasekhara</surname>
<given-names>V</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The management of antithrombotic agents for patients undergoing GI endoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>2016</year>; <volume>83</volume>: <fpage>3</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">26621548</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270060-cit-0011">
<string-name>
<surname>Nagata</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yasunaga</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Matsui</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Therapeutic endoscopy&#x02010;related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: Results from a large nationwide database analysis</article-title>. <source>Gut</source>
<year>2018</year>; <volume>67</volume>: <fpage>1805</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">28874418</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270060-cit-0012">
<string-name>
<surname>Onal</surname>
<given-names>IK</given-names>
</string-name>, <string-name>
<surname>Parlak</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Akdogan</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Do aspirin and non&#x02010;steroidal anti&#x02010;inflammatory drugs increase the risk of post&#x02010;sphincterotomy hemorrhage&#x02013;A case&#x02010;control study</article-title>. <source>Clin Res Hepatol Gastroenterol</source>
<year>2013</year>; <volume>37</volume>: <fpage>171</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22677232</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270060-cit-0013">
<string-name>
<surname>Patai</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Solymosi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Patai</surname>
<given-names>AV</given-names>
</string-name>. <article-title>Does rectal indomethacin given for prevention of post&#x02010;ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?: Post hoc analysis using prospective clinical trial data</article-title>. <source>Medicine</source>
<year>2014</year>; <volume>93</volume>: <elocation-id>e159</elocation-id>.<pub-id pub-id-type="pmid">25474427</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270060-cit-0014">
<string-name>
<surname>Kwok</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Faigel</surname>
<given-names>DO</given-names>
</string-name>. <article-title>Management of anticoagulation before and after gastrointestinal endoscopy</article-title>. <source>Am J Gastroenterol</source>
<year>2009</year>; <volume>104</volume>: <fpage>3085</fpage>&#x02013;<lpage>97</lpage>; quiz 98.<pub-id pub-id-type="pmid">19672250</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270060-cit-0015">
<string-name>
<surname>Zakko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zakko</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grimshaw</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Laine</surname>
<given-names>L</given-names>
</string-name>. <article-title>Antiplatelet monotherapy is associated with an increased risk of bleeding after endoscopic sphincterotomy</article-title>. <source>Dig Dis Sci</source>
<year>2022</year>; <volume>67</volume>: <fpage>4161</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">34796411</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270060-cit-0016">
<string-name>
<surname>Cotton</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Eisen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Aabakken</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>A lexicon for endoscopic adverse events: Report of an ASGE workshop</article-title>. <source>Gastrointest Endosc</source>
<year>2010</year>; <volume>71</volume>: <fpage>446</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">20189503</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270060-cit-0017">
<string-name>
<surname>Ye</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>T</given-names>
</string-name>. <article-title>Analysis of risk factors in endoscopic retrograde cholangiopancreatography&#x02010;related immediate and delayed hemorrhage</article-title>. <source>Dig Dis Sci</source>
<year>2021</year>; <volume>66</volume>: <fpage>4467</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">33469808</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270060-cit-0018">
<string-name>
<surname>Yan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>CX</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Risk factors for delayed hemorrhage after endoscopic sphincterotomy</article-title>. <source>Hepatobiliary Pancreat Dis Int</source>
<year>2020</year>; <volume>19</volume>: <fpage>467</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">31983673</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270060-cit-0019">
<string-name>
<surname>Masuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Koizumi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nishino</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: A retrospective study</article-title>. <source>BMC Gastroenterol</source>
<year>2021</year>; <volume>21</volume>: <fpage>401</fpage>.<pub-id pub-id-type="pmid">34689751</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270060-cit-0020">
<string-name>
<surname>De Caterina</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis&#x02010;Task Force on anticoagulants in heart disease position paper</article-title>. <source>J Am Coll Cardiol</source>
<year>2012</year>; <volume>59</volume>: <fpage>1413</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">22497820</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270060-cit-0021">
<string-name>
<surname>Huang</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>FY</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ai</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>YB</given-names>
</string-name>. <article-title>Effects of antithrombotic therapy on bleeding after endoscopic sphincterotomy: A systematic review and meta&#x02010;analysis</article-title>. <source>Endosc Int Open</source>
<year>2022</year>; <volume>10</volume>: <fpage>E865</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">35692927</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270060-cit-0022">
<string-name>
<surname>Ishii</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Isayama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ushio</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Best procedure for the management of common bile duct stones via the papilla: Literature review and analysis of procedural efficacy and safety</article-title>. <source>J Clin Med</source>
<year>2020</year>; <volume>9</volume>: <fpage>3808</fpage>.<pub-id pub-id-type="pmid">33255554</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270060-cit-0023">
<string-name>
<surname>Ishii</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fujisawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ushio</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Evaluation of the safety and efficacy of minimal endoscopic sphincterotomy followed by papillary balloon dilation for the removal of common bile duct stones</article-title>. <source>Saudi J Gastroenterol</source>
<year>2020</year>; <volume>26</volume>: <fpage>344</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">32719239</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270060-cit-0024">
<string-name>
<surname>Stefanidis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Viazis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pleskow</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Large balloon dilation vs. mechanical lithotripsy for the management of large bile duct stones: A prospective randomized study</article-title>. <source>Am J Gastroenterol</source>
<year>2011</year>; <volume>106</volume>: <fpage>278</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">21045816</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270060-cit-0025">
<string-name>
<surname>Nelson</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Major hemorrhage from endoscopic sphincterotomy: Risk factor analysis</article-title>. <source>J Clin Gastroenterol</source>
<year>1994</year>; <volume>19</volume>: <fpage>283</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7876506</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270060-cit-0026">
<string-name>
<surname>Kim</surname>
<given-names>KO</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JY</given-names>
</string-name>. <article-title>Characteristics of delayed hemorrhage after endoscopic sphincterotomy</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2010</year>; <volume>25</volume>: <fpage>532</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20074163</pub-id>
</mixed-citation></ref><ref id="deo270060-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270060-cit-0027">
<string-name>
<surname>Ling</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The risk of aspirin induced postoperative hemorrhage: A systematic review and meta&#x02010;analysis</article-title>. <source>Expert Rev Gastroenterol Hepatol</source>
<year>2022</year>; <volume>16</volume>: <fpage>981</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">36245097</pub-id>
</mixed-citation></ref></ref-list></back></article>